Targeting Histone Chaperone FACT Complex Overcomes 5-Fluorouracil Resistance in Colon Cancer.
Fluorouracil (5-FU) remains a first-line chemotherapeutic agent for colorectal cancer (CRC). However, a subset of CRC patients who have defective mismatch repair (dMMR) pathway show resistance to 5-FU. Here, we demonstrate that the efficacy of 5-FU in dMMR CRC cells is largely dependent on the DNA base excision repair (BER) pathway. Downregulation of APE1, a key enzyme in BER pathway, decreases IC50 of 5-FU in dMMR CRC cells by 10-fold. Furthermore, we discover that Facilitates Chromatin Transcription (FACT) complex facilitates 5-FU repair in DNA via promoting the recruitment and acetylation of APE1 (AcAPE1) to damage sites in chromatin. Downregulation of FACT affects 5-FU damage repair in DNA and sensitizes dMMR CRC cells to 5-FU. Targeting FACT complex with curaxins, a class of small molecules, significantly improves 5-FU efficacy in dMMR CRC in vitro (~50-fold decrease in IC50) and in vivo xenograft models. We show that primary tumor tissues of CRC patients have higher FACT and AcAPE1 levels compared to adjacent non-tumor tissues. Additionally, there is a strong clinical correlation of FACT and AcAPE1 levels with CRC patients' response to chemotherapy. Together, our study demonstrates that targeting FACT with curaxins is a promising strategy to overcome 5-FU resistance in dMMR CRC patients.